A vault nanoparticle vaccine induces protective mucosal immunity.
about
Novel CCL21-vault nanocapsule intratumoral delivery inhibits lung cancer growthVault nanocapsules as adjuvants favor cell-mediated over antibody-mediated immune responses following immunization of miceProtection against Chlamydia promoted by a subunit vaccine (CTH1) compared with a primary intranasal infection in a mouse genital challenge model.Poly(lactic acid)-poly(ethylene glycol) nanoparticles provide sustained delivery of a Chlamydia trachomatis recombinant MOMP peptide and potentiate systemic adaptive immune responses in mice.In silico resurrection of the major vault protein suggests it is ancestral in modern eukaryotes.CD4+ T cells and antibody are required for optimal major outer membrane protein vaccine-induced immunity to Chlamydia muridarum genital infection.Vaults are dynamically unconstrained cytoplasmic nanoparticles capable of half vault exchange.Vaccination against Chlamydia genital infection utilizing the murine C. muridarum model.Activation of the NLRP3 inflammasome by vault nanoparticles expressing a chlamydial epitope.Targeted vault nanoparticles engineered with an endosomolytic peptide deliver biomolecules to the cytoplasm.Blood stage merozoite surface protein conjugated to nanoparticles induce potent parasite inhibitory antibodiesFormulation, high throughput in vitro screening and in vivo functional characterization of nanoemulsion-based intranasal vaccine adjuvants.Chlamydia trachomatis recombinant MOMP encapsulated in PLGA nanoparticles triggers primarily T helper 1 cellular and antibody immune responses in mice: a desirable candidate nanovaccine.Transplantomics and biomarkers in organ transplantation: a report from the first international conference.Guinea pig genital tract lipidome reveals in vivo and in vitro regulation of phosphatidylcholine 16:0/18:1 and contribution to Chlamydia trachomatis serovar D infectivity.Nanoclusters self-assembled from conformation-stabilized influenza M2e as broadly cross-protective influenza vaccines.Smart vaults: thermally-responsive protein nanocapsules.A Protective Vaccine against Chlamydia Genital Infection Using Vault Nanoparticles without an Added Adjuvant.Towards a Chlamydia trachomatis vaccine: how close are we?Dendrimer-conjugated peptide vaccine enhances clearance of Chlamydia trachomatis genital infection.Update on Chlamydia trachomatis Vaccinology.Chlamydia vaccines: recent developments and the role of adjuvants in future formulations.Toxicity of nanocrystal quantum dots: the relevance of surface modifications.Nanoscale assemblies and their biomedical applications.Engineering protein self-assembling in protein-based nanomedicines for drug delivery and gene therapy.Recombinant protein materials for bioengineering and nanomedicine.Protein nanoparticles for therapeutic protein delivery.Overcoming T. gondii infection and intracellular protein nanocapsules as biomaterials for ultrasonically controlled drug release.Vaccine technologies: From whole organisms to rationally designed protein assemblies.Stem cell-based therapies for HIV/AIDS.Protein based therapeutic delivery agents: Contemporary developments and challenges.Vault nanoparticles engineered with the protein transduction domain, TAT48, enhances cellular uptake.Vaults engineered for hydrophobic drug delivery.Poly(anhydride) nanoparticles act as active Th1 adjuvants through Toll-like receptor exploitation.Toxoid Vaccination against Bacterial Infection Using Cell Membrane-Coated Nanoparticles.Solution Structures of Engineered Vault Particles.
P2860
Q21560837-4C8C43E3-4A26-4803-8F98-BD38F74E4F20Q28727249-238A651C-D068-4742-9806-0313404EEB0BQ33588632-7DDDED04-60FD-4D4C-9713-92C057CDCD97Q33993714-07A7CDE1-0067-45DC-AFE3-18E1D6785B75Q34037615-C9D46721-2A26-4F42-8B76-575522160D4EQ34177368-EED7FEAF-5125-43B4-9EE2-A3EE031A582FQ34485547-116C12F2-4058-4DAC-94D4-A74B5BD698BDQ34739969-A5B36EF5-9E1E-47BF-B632-0E49EF9C0012Q34749353-19F6DACF-1406-4B3D-B4B7-F648A7734091Q35185966-86AFD8AB-AF27-419B-981F-925A1BD74859Q35456892-B1397E4C-3CDC-4E55-AC49-469E1C4877C2Q35593603-1FDA469A-67C7-4150-ADBB-22627B7183E3Q36929225-A57206EC-DCB1-40EA-85D9-3D80DAD21605Q37146013-0E83D05F-F13D-4E00-BADB-11BCA459AFB8Q37255052-CA70D566-5A52-45FD-ADE9-0178FB87EE5EQ37627859-F2C26FCB-300C-4F06-914D-3F760FC5CA33Q37710407-DDF94BBF-310D-41EF-9704-3C4EB8D207B1Q37727719-A7A89DC5-FE01-4974-8607-BA7CC5600694Q37820669-BD5D7237-B0DA-4895-BDFF-737C50230427Q37834084-8EF08848-69E0-4201-BFC3-3D221CCC36BCQ37834874-EB2A1BF5-2134-4A07-80F0-A7474A827CFCQ37849913-A0804197-8416-4A5D-A0BF-B0D8FE668EC1Q37858903-E23661DC-B496-4D2A-B0FB-6AFE3017AFAAQ38072847-D123C0EF-858A-4CBC-B36E-448C4BF8ADF2Q38150365-2BA2415D-4CEF-4016-805F-18C67AC7DE0FQ38298810-A541DDE1-5B55-4F8D-A69D-D00239CABD97Q38556744-1F41F4EF-D67A-4386-8EBD-6EF82A0839CBQ38641476-80653FFA-4BBE-4D7C-A84B-CB5B833DA0AFQ38806558-C6514D55-4EB7-442F-A8EA-0B94862994FAQ38827119-0767CD31-2F08-4158-A92A-54BCA1A12A95Q39273739-E3642F19-20F2-4769-AA46-F88AD09DE68BQ39316251-C6594E7B-E24C-48BA-9370-EA31CE16DF65Q39555815-698BC5A5-CAAF-4E4A-88D6-872025A8D67EQ42117985-870AFC21-EC41-4E95-917D-CFDF7FAF8BEDQ48116102-A486129E-95A9-4390-88D0-B53B1D3522ADQ54254032-2A178916-60BF-4004-ACB8-87B46D8C40C9
P2860
A vault nanoparticle vaccine induces protective mucosal immunity.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 30 April 2009
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
A vault nanoparticle vaccine induces protective mucosal immunity.
@en
A vault nanoparticle vaccine induces protective mucosal immunity.
@nl
type
label
A vault nanoparticle vaccine induces protective mucosal immunity.
@en
A vault nanoparticle vaccine induces protective mucosal immunity.
@nl
prefLabel
A vault nanoparticle vaccine induces protective mucosal immunity.
@en
A vault nanoparticle vaccine induces protective mucosal immunity.
@nl
P2093
P2860
P1433
P1476
A vault nanoparticle vaccine induces protective mucosal immunity.
@en
P2093
Amanda S Freed
Ann M Chan
Cheryl I Champion
Dana Vaccari
Guangchao Liu
Kathleen A Kelly
Liisa L Bergmann
Raymond J Moniz
Sujna Raval-Fernandes
P2860
P356
10.1371/JOURNAL.PONE.0005409
P407
P577
2009-04-30T00:00:00Z